Tue 10/19/2021 12:58 PM
Share this article:
Seqens has a dominant position and technological lead in the salicylics and paracetamol production chains, and has benefited from positive earnings momentum. The France-based active pharmaceutical ingredient, or API, producer delevered over two turns in 2020, with further improvement expected this year, while the acquisition of Wavelength and disposal of its Mineral Specialties business will reduce end-market volatility.

The group benefited significantly from the impact of Covid-19,
Share this article:
This article is an example of the content you may receive if you subscribe to a product of Reorg Research, Inc. or one of its affiliates (collectively, “Reorg”). The information contained herein should not be construed as legal, investment, accounting or other professional services advice on any subject. Reorg, its affiliates, officers, directors, partners and employees expressly disclaim all liability in respect to actions taken or not taken based on any or all the contents of this publication. Copyright © 2021 Reorg Research, Inc. All rights reserved.
Thank you for signing up
for Reorg on the Record!